This section is not available in the published analysis.
SCO-101: Audience
SCO-101 is a first-in-class drug developed by Scandion Oncology that targets chemotherapy resistance mechanisms in cancer patients. It aims to improve treatment outcomes for patients suffering from advanced colorectal cancer and other types of cancer by overcoming drug resistance.